ProLynx
Operator of a biotechnology company intended to develop ultra-long-acting medicines for obesity and other metabolic diseases. The company's system offers linker technologies that are pre-programmed to...
Valuation
$129M
Market implied
Share Price
N/A
Total Raised
$70.1M
Last Round
N/A